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Management of Infection with Nontuberculosis
Mycobacteria
Stephen H. Gillespie
1. INTRODUCTION
The nontuberculosis mycobacteria are often naturally resistant to the conventional
antibiotics and to antituberculosis drugs (1–3). In addition, providing advice for the
treatment of nontuberculosis is complicated by the variable and changing designations
of these organisms, the heterogeneity of the clinical syndromes and patients, and the
relative lack of controlled clinical trials (1,2). This chapter discusses the management
of these difficult infections.
1.1. Nomenclature
The clinical importance of Mycobacterium tuberculosis as a major cause of death
has meant that microbiologists have rightly focused on this organism. The remaining
Mycobacterium species, which appeared to lack the potential to cause infection in
healthy individuals, were often dismissed as “anonymous” or “atypical” (4). This
approach was neither accurate nor clinically helpful. As environmental organisms, their
low pathogenic potential and failure to produce diseases that resemble tuberculosis is
expected. Thus, the term nontuberculosis mycobacterium (NTM) is preferred (2).
Now that conventional and molecular taxonomic techniques have been applied to
this group of organisms, clinicians will increasingly be able to identify the invading
mycobacteria accurately and to detect previously unrecognized species. As the patho-
genic potential of each species is more accurately defined, it will become easier to
choose the most appropriate drugs and management strategies.
1.2. Epidemiology
Mycobacteria are organisms that mainly live in the inanimate environment or as
colonizers of humans and animals (5). In one sense, it is the pathogenic species M.
tuberculosis and Mycobacterium leprae that are atypical in that they lack an environ-
mental reservoir. Most other species of the Mycobacterium genus are found in the envi-
ronment and can be isolated from soil, water, and carriage sites in animals and humans (6).
The number of cases of NTM infection has been increasing throughout the world
(7). The reasons for this are varied, but are important and need to be considered to
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understand the interaction of the epidemiology of NTM and therapeutic strategies.
There has been a genuine increase in the number of cases because of changes in medi-
cal practice that provide opportunities for colonization and infection, for example, colo-
nization of intravenous long lines with rapidly growing mycobacteria (8). The increase
in the number of patients who are receiving immunosuppressive therapy also provides
opportunities for NTM to cause disease. The human immunodeficiency virus (HIV)
epidemic brought about an enormous increase in the number of Mycobacterium avium-
intracellulare cases (9,10).
The number of cases has also been increasing because the diagnostic methods
employed for mycobacteria have improved significantly over the last 20 yr (11). In
addition, simpler identification techniques, including molecular methods, have simpli-
fied diagnosis sufficiently that it is no longer the province of a reference laboratory.
This has led to increased recognition, which has helped define the patterns of disease
caused by different species and in the description of many new species (12–14).
1.3. Scope of the Chapter
This chapter discusses the diagnosis and management of the NTM that are difficult
to treat by virtue of their natural resistance to antibiotics. The major clinical syndromes
discussed include bacteremia with M. avium-intracellulare, cervical lymphadenopathy
and pulmonary infection with NTM, and infection with rapidly growing mycobacteria.
2. DIAGNOSIS OF NONTUBERCULOSIS MYCOBACTERIA
The isolation of M. tuberculosis from a specimen is sufficient to indicate a diagnosis
of tuberculosis. The only other possible explanation of this finding is cross-
contamination of the specimen either in the clinical setting or in the laboratory. The
diagnostic problem is more difficult for NTM. As many of these organisms can form
part of the normal flora or represent environmental contaminants, a single isolate is
often not sufficient to make a diagnosis (1,2).
2.1. Pulmonary Disease
The radiological appearances of NTM pulmonary disease exhibit subtle differences
from that of tuberculosis. Cavities, when present, are thin walled, and there is less
surrounding infiltrate. Spread is more contiguous with more marked involvement of
the pleura. Occasionally, NTM may cause a single pulmonary nodule. An important
part of confirming a diagnosis of NTM infection is to exclude potential confounding
diagnoses, such as tuberculosis and lung malignancy. As Mycobacterium kansasii,
Mycobacterium xenopi, Mycobacterium malmoense, and the rapid growers can form
part of the normal flora, multiple isolates of an NTM are required from sputum or
bronchial washings obtained at different times to support a positive diagnosis (10).
More weight is to be placed on single specimens that are also smear positive (1,2).
Alternatively, a single isolate from a biopsy specimen is diagnostic provided it is sup-
ported by compatible histology (2).
Sputum is usually an adequate specimen with which to obtain a positive diagnosis of
infection with M. kansasii, M. xenopi, and M. malmoense. In contrast, in HIV-serone-
gative individuals infected with M. avium-intracellulare, sputum is insensitive, and a
more aggressive approach using bronchial lavage should be adopted (15).
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2.2. Lymphadenitis
The most important part of diagnosis of lymphadenitis is to exclude tuberculosis.
The diagnosis depends on granulomata in a biopsy of lymph glands in the context of a
negative tuberculin test. A single isolate from a biopsy specimen is sufficient to make
the diagnosis, although yields may be less than 50% of cases (16,17). This in part may
be because of the methods employed and the presence of fastidious mycobacterial spe-
cies such as Mycobacterium haemophilum and Mycobacterium genavense.
2.3. Cutaneous Infection
The presence of rapidly growing mycobacteria in skin specimens must be evaluated
carefully. Multiple isolates are required in clinical circumstances that support the diag-
nosis, for example, the presence of a plastic catheter or prosthetic device. Alterna-
tively, individual cases may form part of known outbreaks with contaminated injections
or prostheses. For Mycobacterium ulcerans and Mycobacterium marinum, the situa-
tion is often simpler as these species are likely to be isolated from patients with charac-
teristic cutaneous lesions, making diagnosis easy. The management of these specific
cutaneous infections is not discussed further.
2.4. Disseminated Infection in HIV-Infected Individuals
Disseminated infection with M. avium-intracellulare is usually only found in patients
with advanced HIV infection who have not received antiretroviral therapy or have failed
to take it. The CD count is usually low (<50), and the patient has clinical signs of
advanced disease (18). Patients are usually febrile and wasted and with significant
anemia. Alkaline phosphatase is often elevated as hepatic involvement by M. avium-
intracellulare is common. Usually, a single isolate from the blood is sufficient to con-
firm the diagnosis of disseminated M. avium-intracellulare infection (1,2).
2.5. Role of Susceptibility Testing
The role of susceptibility testing in treatment choice for NTMs is controversial.
There are many older studies that indicate that in vitro susceptibility test results do not
correlate well with clinical outcome (19,20). A more recent study of M. avium com-
plex, M. malmoense, and M. xenopi found only one significant correlation of resistance
and treatment failure for M. xenopi (21). Similarly, a study of M. avium-intracellulare
infection in HIV-seronegative patients found no correlation between the in vitro sus-
ceptibility and outcome (22). However, such relationships are difficult to demonstrate
unequivocally because all therapeutic regimens are with multiple drugs, and most cen-
ters only have a few patients, with the effect that these studies lack statistical power.
One study of 256 patients showed a significant association (p < 0.001) between partial
or no in vitro resistance to 1 mg/L of isoniazid and the time required for conversion of
sputum from culture positive to negative, whereas complete resistance to isoniazid had
a statistically significant adverse effect (23). Others have found susceptibility testing
for rapid growers valuable for planning chemotherapy (24). Also, patients who
responded to treatment for pulmonary M. avium-intracellulare received significantly
more drugs to which their isolate was susceptible (25).
Much of the contradiction provided by these articles may be because mycobacterial
susceptibility tests are designed for use with M. tuberculosis. NTM may be inhibited
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with antibiotic concentrations achievable in serum, but at concentrations higher than
that required for tuberculosis. Thus, in vitro test results based on a breakpoint for tuber-
culosis will produce false resistance for an isolate of NTM (21,22). The use of methods
that provide minimum inhibitory concentration (MIC) data will enable regimens to be
constructed specifically for NTM that take into account the achievable concentrations
of antibiotics (26,27).
3. MANAGEMENT OF MYCOBACTERIUM KANSASII INFECTION
3.1. Pulmonary Infections
Mycobacterium kansasii is an important pulmonary pathogen with a tendency to
affect older male patients with pre-existent pulmonary disease. Mortality rates are high,
but this is often because of the severe underlying conditions that coexist in these patients
(28). All authorities agree that it is the inclusion of rifampicin that is responsible for
favorable outcomes of culture conversion in almost all patients within 4 mo. On the
other hand, resistance to this agent or its absence in the regimen underlies many of the
reported examples of treatment failure (23,29,30). With regimens that contain rifampi-
cin, relapse rates are typically low, with figures of between 2.5 and 9% (23,28).
The current American Thoracic Society (ATS) recommendation for treatment of
pulmonary disease caused by M. kansasii in adults is the regimen of isoniazid (300
mg), rifampin (600 mg), and ethambutol (25 mg/kg body weight for the first 2 mo, then
15 mg/kg body weight) given daily for 18 mo and with at least 12 mo of negative
sputum cultures. In patients who are unable to tolerate one of these three drugs,
clarithromycin would seem a reasonable alternative, but its effectiveness has not been
established by clinical trials (see below). Pyrazinamide has no role to play in therapy
for M. kansasii infections because all isolates are resistant (2).
A prospective clinical trial performed by the British Thoracic Society (BTS) in 173
patients with two sputum cultures positive for NTM showed that M. kansasii pulmo-
nary infection responded well to 9 mo of treatment with rifampicin and ethambutol, but
patients who contract this disease have a high mortality rate from other causes. Iso-
niazid did not appear to be a necessary part of the regimen (28). Consequently, the BTS
recommend that 9 mo of rifampicin and ethambutol is adequate treatment for most
patients, but when there is evidence of compromising conditions, treatment can be
extended to 15–24 mo (1). The use of intermittent drug regimens or short-course
therapy has not been studied sufficiently for advice to be given.
In patients who have an inadequate response or who are unable to tolerate the stan-
dard agents, prothionamide (1 g/d orally) and streptomycin (0.75–1 g/d im) could be
added (1), but both are associated with frequent adverse events. Both clarithromycin
and fluoroquinolones are highly active against M. kansasii and are likely to be benefi-
cial (3,31), although there is no clinical trial data available. These agents have proved
useful in the treatment of M. avium-intracellulare infection (see below) and may be
useful as part of the regimen.
Rifampicin resistance among M. kansasii appears to be increasing in part because of
the HIV epidemic. Although rifampicin is the most important drug in the treatment of
M. kansasii infection if patients are treated with a regimen that includes three drugs to
which the infecting organism is susceptible a good outcome is likely. Many of these
regimens include clarithromycin and ciprofloxacin (26).
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3.2. Extrapulmonary Infection
The treatment of extrapulmonary disease should probably be similar to the pulmo-
nary regimens. For lymphadenopathy, excision is recommended as this is the optimal
treatment for M. avium-intracellulare infection, the most common cause (see below)
(1,2).
4. MANAGEMENT OF MYCOBACTERIUM MALMOENSE DISEASE
4.1. Pulmonary Disease
Retrospective studies have shown that patients treated for 18–24 mo with regimens
that included rifampicin and ethambutol did better than those treated with other regi-
mens or who had shorter durations of treatment (32). The addition of second- or third-
line drugs increased the rate at which adverse events were reported without improving
the outcome. Surgery has an important role to play for those who are suitable for
operation, and chemotherapy should be continued afterward for at least 18 mo. A clinical
trial of chemotherapy in M. malmoense infection showed that treatment of M.
malmoense with rifampicin and ethambutol for 2 yr is preferable to a regimen that
contains isoniazid, although there was a nonsignificant reduction in the relapse rate for
the three-drug regimen. However, there was a higher death rate for the three-drug regi-
men (1).
Macrolides and quinolones are active in vitro (3,31), and there are some anecdotal
reports of treatment response when these agents are used in the management of patients
who are very susceptible to infection (33). New clinical trials have been designed and
are under way to evaluate the role of macrolides and quinolones in therapeutic regi-
mens and to detect the value of immunizing with Mycobacterium vaccae (1).
4.2. Mycobacterium malmoense Extrapulmonary Disease
Lymphadenitis is the most common form of M. malmoense extrapulmonary disease,
and this syndrome should be treated with excision. Otherwise, extrapulmonary disease
should be treated in the same way as pulmonary disease.
5. MANAGEMENT OF MYCOBACTERIUM XENOPI DISEASE
5.1. Pulmonary Disease
Mycobacterium xenopi poses many diagnostic and therapeutic problems. In some
patients, M. xenopi may act as a colonizer without causing disease (34–36). Therefore,
it will be present in multiple specimens, thus passing the test for “significance,”
although in many such cases it is not responsible for clinical symptoms. In addition,
infection with M. xenopi is normally indolent, with disease developing over a number
of years (32). Thus, an isolate in an apparently asymptomatic patient cannot be lightly
dismissed, especially in HIV-infected individuals. To overcome the diagnostic diffi-
culty, it has been proposed that the criteria for diagnosis of M. xenopi infection be two
sputum isolations in the absence of other likely causes of symptoms (37).
Early studies have suggested that regimens should contain rifampicin and isoniazid
together with ethambutol or streptomycin (32,38). A clinical trial suggested that a regi-
men of rifampicin and ethambutol is optimum, although there is a trend to a higher cure
rate when isoniazid is added, but the complication rate is increased (39). In view of the
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higher complication rate with added isoniazid, guidelines suggest that this drug should
be included only if treatment fails to render the sputum culture negative (1).
Macrolides and quinolones may have an important role in the treatment of M. xenopi
infections as they are active in vitro and in animal models (3,31,40). There are anec-
dotal reports of the value of these agents (33). Clinical trial data are not yet available to
inform therapeutic choice, but these could rationally be added to treatment of patients
who fail to respond.
The results of medical therapy can be poor, with a 5-yr mortality of up to 57%
(although a minority of these deaths were directly attributed to mycobacterial infec-
tion) (39). Pulmonary resection is often necessary as an adjunct to treatment (41). Pul-
monary resection should be considered in patients who are failing on therapy, but who
otherwise have good pulmonary function and whose disease is localized. When these
criteria are applied, sputum conversion is complete in all but the patients who have
incomplete resection (42).
6. MANAGEMENT OF MYCOBACTERIUM AVIUM-INTRACELLULARE
DISEASE
Infection with M. avium-intracellulare was once rare and was found as sporadic
disease and in severely immunocompromised patients (2,10). This situation was trans-
formed by the HIV epidemic, in which disseminated M. avium-intracellulare infection
and bacteremia were common late complications, usually when the CD4 count fell
below 50. Management of M. avium-intracellulare infection is so influenced by the
severity of HIV infection, it is considered separately.
6.1. HIV-Seronegative Patients
6.1.1. Mycobacterium avium-intracellulare Pulmonary Disease
Pulmonary disease caused by M. avium complex in HIV-seronegative patients usu-
ally occurs in those with concomitant chronic lung disease or deficient cellular immu-
nity, and its prevalence is increasing (10). The predisposing conditions include
pneumoconiosis and silicosis because of chronic and long-term exposure to occupa-
tional dusts (e.g., from coal mining and farming) (43). For example, in one study, 73%
of patients had pre-existing pulmonary disease, 38% smoked, and 33% reported alco-
hol abuse.
The prognosis in M. avium complex pulmonary infections was strongly correlated
with the underlying condition (44). Older studies of treatment and the natural history of
disease showed that patients who are symptomatic have progressive disease that is
difficult to treat, whereas many of those who were asymptomatic at the time of isola-
tion went on to develop invasive disease (20).
Isolated pulmonary disease in otherwise healthy women has been described (45).
Surveys suggest that approximately half of these patients fail therapy (15).
Treatment with three drugs, including rifampicin and isoniazid, coupled with either
streptomycin or ethambutol were thought to give the best results (20). A clinical trial of
treatment of M. avium-intracellulare pulmonary infection in HIV-seronegative patients
suggested that the optimum treatment regimen is with rifampicin and ethambutol, and that
isoniazid reduced the failure and relapse rate (39). Five-year follow-up of patients treated
with this regimen showed that 15% of patients failed therapy, and 14% relapsed (46).
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The activity of clarithromycin and quinolones suggests that they may have a role to
play, and clinical trials are under way to evaluate this (39). Open trials suggested that
sputum conversion rates greater than 75% can be achieved with regimens that include
a macrolide (47–49). Thus, although no comparative clinical trials have yet been
reported, macrolides should probably now always be included in regimens used to treat
M. avium-intracellulare infections in immunocompetent patients. Intermittent therapy
(three times a week) is also reported to have a similar conversion rate (50).
A recent article may give some insight into the reasons for the high relapse rate.
Study of the organisms obtained from patients treated with clarithromycin who had
suffered late relapses after 4 consecutive months of negative culture showed that the
majority of these isolates were different from the original infecting strain. This sug-
gests that many late relapses are caused by reinfection from this common environmen-
tal organism among patients who are highly predisposed to infection (49).
Some authorities suggest that rifabutin should be the rifamycin of choice for treat-
ment of M. avium-intracellulare infection because of its greater in vitro activity. How-
ever, this drug has a different adverse event profile, and only comparative clinical trials
can tell whether the additional activity is gained without increased adverse events.
6.1.2. Management of Lymphadenitis
Mycobacterium avium-intracellulare is the commonest cause of cervical lymphad-
enopathy in children in countries where tuberculosis has been controlled (51). Surgical
excision is essential for diagnosis as the yield from fine-needle aspiration is not com-
plete, and there is a considerable risk of sinus formation (2). Optimal treatment of this
condition is surgical excision, which has a lower reoperation rate than incision and
drainage, curettage, or aspiration (17). Relapse and sinus formation are rare, occurring
in less than 5% of cases (16,52). Antimicrobial chemotherapy appears to be unneces-
sary (2), although there are reports of successful management with clarithromycin
monotherapy (53).
6.1.3. Management of Disseminated Infection in HIV-Seropositive Patients
Disseminated M. avium-intracellulare infection is a late complication of HIV infection.
Since the introduction of highly active antiretroviral therapy (HAART), it has become
much less common in developed countries, occurring in patients who are untreated or
who have been unable to tolerate therapy. The optimal regimen has not yet been estab-
lished, partly because patients with this infection are at a very late stage of HIV disease
for which the clinical course is complicated by other opportunistic infections and the
consequence of HIV itself. In the era of HAART, the management of disseminated M.
avium-intracellulare infection is underwritten by therapeutic efforts to reduce the HIV
viral load, increase the CD4 count, and bring about reversal of the immune deficit.
Antibiotics have an important role in reducing bacteremia, and the antibiotics able
to do that include macrolides such as clarithromycin and azithromycin, quinolones
such as ciprofloxacin, and rifabutin, a rifamycin. The macrolides are highly active and
are the cornerstones of all regimens. They are capable of reducing the count of bacteria
in the blood when given alone (54,55). Monotherapy results in the rapid emergence of
resistance; thus, combination therapy should be chosen.
Clinical trials have supported the superiority of clarithromycin, ethambutol, and
rifabutin over rifampicin, ethambutol, clofazimine, and ciprofloxacin (56). A compara-
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tive trial suggested that lower doses of rifabutin (300 mg daily) together with ethambu-
tol are more effective than a four-drug regimen of rifampicin, ethambutol, clofazimine,
and ciprofloxacin, still retaining much of the activity of clarithromycin (1000 mg twice
daily) and rifabutin (600 mg daily) doses (56).
6.1.4. Prophylaxis of Mycobacterium avium-intracellulare
Prophylaxis is necessary to prevent infection in patients with late-stage HIV infec-
tion with low CD4 count. Macrolides have been shown to be more effective than
rifabutin, which also is an effective agent, but is associated with a higher rate of intol-
erance (57,58). Ultimately, the choice of prophylactic agent will depend on the choice
of HAART because rifabutin interacts with protease inhibitors, and patients differ con-
siderably in their ability to tolerate drugs (59).
7. MANAGEMENT OF INFECTION WITH RAPID GROWERS
7.1. Pulmonary Disease
More than 80% of cases of pulmonary disease are caused by M. abscessus, which is
the naturally most resistant member of the group of organisms (60). Treatment of M.
abscessus infections is often disappointing. Treatment can bring about clinical improve-
ment, but cure is rare. When surgery is technically possible, it is recommended (1).
Susceptibility testing of rapidly growing mycobacteria is thought to give a good guide
to treatment, and regimens should be constructed based on susceptibility test results
(24). Regimens should probably include rifampicin (450 mg if the patient weighs less
than 50 kg, 600 mg if the patient weighs more than 50 kg), ethambutol (15 mg/kg body
weight), and clarithromycin (500 mg twice daily). There are reports of the value of
fluoroquinolones, sulfonamides, amikacin, cefoxitin, and penems in treatment
(1,24,61).
7.2. Extrapulmonary Disease
Many cases of infection by rapid growers occur in the context of an infected pros-
thetic device, for example, intravenous canullae or other implants. Successful therapy
of these catheter-related infections involves removal of the catheter and antimicrobial
therapy, usually for 2 to 4 mo. Although disease caused by M. fortuitum may resolve if
the catheter is removed, reinsertion of another catheter in a similar location without
drug therapy usually results in disease recurrence (as in the above case) (8). Adjunctive
therapy should be with ciprofloxacin, amikacin, and clarithromycin for up to 4 mo.
When there is a tunneled line that also has a tissue infection, then treatment may need
to be extended for 6 mo (12).
Postinjection abscesses should be treated by surgical drainage and clarithromycin
for between 3 and 6 mo. This advice comes as a result of the experience obtained from
a series of outbreaks (62,63).
Wound infections are one of the most common manifestations of infection with rap-
idly growing mycobacteria. Infections have often been associated with augmentation
mammoplasty and other plastic surgery procedures (12,64,65). Therapy depends of the
removal of any infected foreign material, followed by 6 mo of chemotherapy (66,67).
Clarithromycin is the main choice, with other drugs added to prevent the emergence of
resistance (68).
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Disseminated cutaneous infection is mainly with M. abscessus, usually in patients
who are compromised by renal failure or corticosteroid therapy (69). This is one of the
most common presentations of nonpulmonary infection with rapidly growing organ-
isms (12). Treatment includes drainage of any abscesses coupled with clarithromycin
for 6 mo and with another agent to which the isolate is susceptible during the first 2 mo (68).
8. SUMMARY
Infections with NTM continue to pose significant diagnostic and therapeutic prob-
lems for clinicians. Infection often occurs in the context of other serious disease, which
may influence the outcome more than the infective process. Diagnosis can be difficult,
but modern laboratory methods are improving rapidly. For several important infec-
tions, clinical trial information is helping to inform clinicians (39). The results of trials
currently under way to elucidate the activity of quinolones and macrolides may soon
improve the evidence base on for defining more effective regimens.
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